On the association between SARS-COV-2 variants and COVID-19 mortality during the second wave of the pandemic in Europe [0.03%]
与欧洲第二波疫情期间的COVID-19死亡率有关的SARS-COV-2变异毒株研究
Katarzyna Jabłońska,Samuel Aballéa,Pascal Auquier et al.
Katarzyna Jabłońska et al.
Objective: This study aims at investigating associations between COVID-19 mortality and SARS-COV-2 variants spread during the second wave of COVID-19 pandemic in Europe. ...
An overview of health technology assessments of gene therapies with the focus on cost-effectiveness models [0.03%]
基因治疗的健康技术评估概述：重点关注成本效益模型
Michał Pochopień,Ewelina Paterak,Emilie Clay et al.
Michał Pochopień et al.
Background: Gene therapies can treat, prevent, or cure a disease by changing the expression of a person's genes. They are an innovative strategy for treating genetic disorders; however, they are still emerging on the mark...
Sahar Barjestehvan Waalwijk van Doorn-Khosrovani,Lonneke Timmers,Anke Pisters-van Roy et al.
Sahar Barjestehvan Waalwijk van Doorn-Khosrovani et al.
Introduction: Outcome-based agreements (OBAs) are occasionally deployed to relieve the burden of high drug prices on healthcare budgets. However, it is not clear when manufacturers are willing to collaborate in establishi...
Bright line or lottery? On significance and value in medical decision making [0.03%]
明显的分界线还是抽签？论医学决策中显著性和价值的重要性
Jörg Mahlich,Srirangan Dheban
Jörg Mahlich
It is widely acknowledged that using p-value thresholds as the basis for making decision on health care spending is not appropriate. In the context of medical decision making, we argue that patient preferences need to be a stronger factor. ...
The impact of increasing multitarget stool DNA use among colorectal cancer screeners in a self-insured US employer population [0.03%]
美国自保雇主人群中的结直肠癌筛查者中不断增加的多目标粪便DNA使用的影响
Joanne M Hathway,Lesley-Ann Miller-Wilson,Abhishek Sharma et al.
Joanne M Hathway et al.
Background: In the United States (US), colorectal cancer (CRC) is the second leading cause of cancer-related deaths. With the majority of the US population covered by employer-based health plans, employers can play a critical role in increa...
Accelerating patient access to oncology medicines with multiple indications in Europe [0.03%]
在欧洲加快肿瘤多适应症药物患者获取速度
R Lawlor,T Wilsdon,E Darquennes et al.
R Lawlor et al.
Background: In recent years, innovation in oncology has created new challenges for pricing and reimbursement systems. Oncology medicines with multiple indications face a number of access challenges: (1) the number of assessments and adminis...
Cost-Effectiveness Analysis of a Prescription Digital Therapeutic for the Treatment of Opioid Use Disorder [0.03%]
阿片类药物使用障碍治疗处方数字疗法的成本效益分析
Fulton F Velez,Daniel C Malone
Fulton F Velez
The lack of adequate treatment for many patients with opioid use disorder (OUD) has led to high medical costs ($90B in 2020). An analysis of the cost-effectiveness (cost-utility) of reSET-O, the first and only FDA-approved prescription digi...
Switching from one reference biological to another in stable patients for non-medical reasons: a literature search and brief review [0.03%]
从一种参考生物类似药转换为另一种参考生物类似药的非医学原因切换：文献回顾及简要综述
Knut Stavem
Knut Stavem
Background: The practice of non-medical switch (NMS) from a reference biological (originator) to a biosimilar is widely accepted in some countries. However, there is little documentation on the impact of NMS from one originator to another o...
Informing decision makers seeking to improve vaccination programs: case-study Serbia [0.03%]
提升疫苗接种计划的决策者的决定：以塞尔维亚为例
Christophe Sauboin,Jovan Mihajlović,Maarten Jacobus Postma et al.
Christophe Sauboin et al.
Background:The optimisation of vaccine policies before their implementation is beholden upon public health decision makers, seeking to maximise population health. In this case study in Serbia, the childhood vaccines under consideration incl...
The effects of market concentration on health care price and quality in hospital markets in Ibadan, Nigeria [0.03%]
尼日利亚伊巴丹医院市场集中度对医疗价格和质量的影响
Bosede Olanike Awoyemi,Olanrewaju Olaniyan
Bosede Olanike Awoyemi
Evidence about the Nigerian health indicators show that the quality of health care in Nigeria is low and inflation of health care prices also persists. Theoretically, by observing the market concentration, inferences can be drawn as to how ...